Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Accounts Payables (2018 - 2025)

Historic Accounts Payables for China SXT Pharmaceuticals (SXTC) over the last 8 years, with Q3 2025 value amounting to $3.3 million.

  • China SXT Pharmaceuticals' Accounts Payables rose 1176.92% to $3.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.3 million, marking a year-over-year increase of 1176.92%. This contributed to the annual value of $2.9 million for FY2025, which is 12959.09% up from last year.
  • As of Q3 2025, China SXT Pharmaceuticals' Accounts Payables stood at $3.3 million, which was up 1176.92% from $2.9 million recorded in Q1 2025.
  • In the past 5 years, China SXT Pharmaceuticals' Accounts Payables registered a high of $3.5 million during Q1 2022, and its lowest value of $1.3 million during Q1 2024.
  • For the 5-year period, China SXT Pharmaceuticals' Accounts Payables averaged around $2.8 million, with its median value being $3.1 million (2021).
  • In the last 5 years, China SXT Pharmaceuticals' Accounts Payables plummeted by 6096.17% in 2023 and then soared by 12959.09% in 2025.
  • Over the past 5 years, China SXT Pharmaceuticals' Accounts Payables (Quarter) stood at $3.4 million in 2021, then decreased by 2.46% to $3.3 million in 2022, then dropped by 0.89% to $3.2 million in 2023, then decreased by 10.05% to $2.9 million in 2024, then increased by 11.77% to $3.3 million in 2025.
  • Its Accounts Payables was $3.3 million in Q3 2025, compared to $2.9 million in Q1 2025 and $2.9 million in Q3 2024.